Expert Review of Hematology

Papers
(The H4-Index of Expert Review of Hematology is 17. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-11-01 to 2025-11-01.)
ArticleCitations
Are we closer to a standard of care for Richter’s syndrome? Novel treatments on the horizon58
From bench to bedside: bridging the gaps in best practices for real-world chronic myeloid leukemia care55
Hematological parameters and X-ray exposure among medical radiation workers: a systematic review and meta-analysis51
COVID-19 associated with immune thrombocytopenia: a systematic review and meta-analysis41
Hemophagocytic lymphohistiocytosis in Egyptian children: diagnosis, treatment challenges, and outcome37
Upfront therapy for diffuse large B-cell lymphoma: looking beyond R-CHOP30
Treatment patterns and blood count control in 10,112 patients with polycythemia vera29
Frequencies of glycosylphosphatidylinositol (GPI)-deficient cells using high-sensitivity flow cytometry as per the 2018 ICCS/ESCCA consensus guideline in patients with hematologic malignancy, aplastic28
Treating sickle cell disease in resource-limited sub-Saharan Africa: recent strategies and recommendations in addressing the gaps for the provision of evidence-based management28
Acalabrutinib: a bruton tyrosine kinase inhibitor for the treatment of chronic lymphocytic leukemia27
What is the future of digital tools to help manage pain in sickle cell disease patients?26
Immune thrombocytopenia and pregnancy: challenges and opportunities in diagnosis and management21
Do we need more guidance on thrombophilia testing? Challenges and special considerations21
The evolving management algorithm for the patient with newly diagnosed cold agglutinin disease20
Past, present, and future of orthopedic surgery in hemophilia: looking to a world without bleeding and arthropathy in the near future19
The future of siRNA-mediated approaches to treat von Willebrand disease17
Etranacogene dezaparvovec for the treatment of adult patients with severe and moderately severe hemophilia B17
0.042021989822388